-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $32

Benzinga·11/06/2025 15:35:13
Listen to the news
RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $34 to $32.